human tpo Search Results


94
Miltenyi Biotec tpo

Tpo, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tpo/Human+TPO%2C+premium+grade/pmc06838675-49-0-2
Average 94 stars, based on 1 article reviews
tpo - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

93
MedChemExpress recombinant human thrombopoietin

Recombinant Human Thrombopoietin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tpo/TPO%2FThrombopoietin%2C+Human/pm40197264-33-4-7
Average 93 stars, based on 1 article reviews
recombinant human thrombopoietin - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

90
OriGene pcmv6 mycddk thrombopoietin

Pcmv6 Mycddk Thrombopoietin, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tpo/Thrombopoietin+(THPO)+(NM_000460)+Human+Tagged+ORF+Clone/pm32337844-42-6-11
Average 90 stars, based on 1 article reviews
pcmv6 mycddk thrombopoietin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

94
Miltenyi Biotec rhtpo

Rhtpo, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tpo/Human+TPO%2C+research+grade/bio_rxiv__64898__2026__03__24__713961-518-29-30
Average 94 stars, based on 1 article reviews
rhtpo - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

92
R&D Systems human tpo

Human Tpo, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tpo/Human+Thrombopoietin+R%2FTpo+R+Antibody/10__1182_slash_blood__v90__10__3893-42-35-39
Average 92 stars, based on 1 article reviews
human tpo - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier

91
R&D Systems tpo
Impairment of hematopoietic function. a) Comparison of changes in CD34 + , b) Comparison of changes in CFU-GM, c) Comparison of changes in BFU-E, d) Comparison of changes <t>in</t> <t>CXCL12,</t> e) Comparison of changes in EPO, f) Comparison of changes in <t>TPO.</t> Note: 'a' indicates P < 0.05 compared with T0, 'b' indicates comparison with T1, and 'c' indicates P < 0.05 compared with the IV group at the same time.
Tpo, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tpo/Human+Thrombopoietin%2FTpo+Biotinylated+Antibody/pmc12967180-81-18-33
Average 91 stars, based on 1 article reviews
tpo - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier

91
OriGene recombinant tpo
Impairment of hematopoietic function. a) Comparison of changes in CD34 + , b) Comparison of changes in CFU-GM, c) Comparison of changes in BFU-E, d) Comparison of changes <t>in</t> <t>CXCL12,</t> e) Comparison of changes in EPO, f) Comparison of changes in <t>TPO.</t> Note: 'a' indicates P < 0.05 compared with T0, 'b' indicates comparison with T1, and 'c' indicates P < 0.05 compared with the IV group at the same time.
Recombinant Tpo, supplied by OriGene, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tpo/Thyroid+Peroxidase+(TPO)+(NM_000547)+Human+Recombinant+Protein/10__1111_slash_all__15925-8622-8-10
Average 91 stars, based on 1 article reviews
recombinant tpo - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier

91
R&D Systems antibody against tpo
Impairment of hematopoietic function. a) Comparison of changes in CD34 + , b) Comparison of changes in CFU-GM, c) Comparison of changes in BFU-E, d) Comparison of changes <t>in</t> <t>CXCL12,</t> e) Comparison of changes in EPO, f) Comparison of changes in <t>TPO.</t> Note: 'a' indicates P < 0.05 compared with T0, 'b' indicates comparison with T1, and 'c' indicates P < 0.05 compared with the IV group at the same time.
Antibody Against Tpo, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tpo/Human+Thrombopoietin%2FTpo+Antibody/pmc07812794__pnas__2017849118__sapp-48-40-43
Average 91 stars, based on 1 article reviews
antibody against tpo - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier

93
Proteintech tpo
Impairment of hematopoietic function. a) Comparison of changes in CD34 + , b) Comparison of changes in CFU-GM, c) Comparison of changes in BFU-E, d) Comparison of changes <t>in</t> <t>CXCL12,</t> e) Comparison of changes in EPO, f) Comparison of changes in <t>TPO.</t> Note: 'a' indicates P < 0.05 compared with T0, 'b' indicates comparison with T1, and 'c' indicates P < 0.05 compared with the IV group at the same time.
Tpo, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tpo/Animal-free+Recombinant+Human+Thrombopoietin/pm41802812-79-48-51
Average 93 stars, based on 1 article reviews
tpo - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

92
MedChemExpress recombinant tpor ectodomain
Impairment of hematopoietic function. a) Comparison of changes in CD34 + , b) Comparison of changes in CFU-GM, c) Comparison of changes in BFU-E, d) Comparison of changes <t>in</t> <t>CXCL12,</t> e) Comparison of changes in EPO, f) Comparison of changes in <t>TPO.</t> Note: 'a' indicates P < 0.05 compared with T0, 'b' indicates comparison with T1, and 'c' indicates P < 0.05 compared with the IV group at the same time.
Recombinant Tpor Ectodomain, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tpo/C-MPL%2C+Human/pm39171830__ja4c08624_si_001-329-22-27
Average 92 stars, based on 1 article reviews
recombinant tpor ectodomain - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier

91
R&D Systems human tpo receptor antibody
a During CCl 4 -induced acute liver injury (ALI), thrombocytosis was detected as an increased peripheral blood (PB) platelet counts in the ALI vs. control (CON) mice ( n = 12 mice, two-way repeated-measures ANOVA with Bonferroni’s multiple comparison tests, p = 0.0045 (Con as control)). Non-treated mice (WT) were set as baseline control. b , c Megakaryocytopoiesis in bone marrow (BM) after CCl 4 injection is shown. On day 8 after injection, representative femur sections stained with CD41 and hematoxylin showed increased levels of CD41-positive cells (Scale bars: 100 μm) ( b ), and a histogram indicated that BM whole megakaryocytic cells (MK, CD41 positive), including mature megakaryocytes (m-MK, CD41, and CD42 double-positive) and megakaryocyte-erythroid progenitors (MEP, CD41, and CD71 double positive), were increased in the ALI mice c . Representative FCM plots are shown in Supplementary Fig. . d The percentage of cells of each ploidy in BM is shown. e , f Liver <t>TPO</t> synthesis was suppressed under ALI, as demonstrated by liver cell qPCR ( e ) and plasma TPO ELISA analyses (two-way repeated measures ANOVA with Bonferroni’s multiple comparison tests, p = 0.0085) ( f ). g PB-PLTs incorporated increased levels of CD62p-positive activated PLT in the ALI mice on day 2 after injection. h – j Platelet-derived <t>microparticles</t> <t>(PMPs)</t> increased in the ALI mice ( n = 12 mice). Compared with those of the control group, the circulating CD41 + microparticles (MPs) increased (two-way repeated-measures ANOVA with Bonferroni’s multiple comparison tests) ( h ), and the proportion of CD41 + /CD62p + PMPs among the CD41 + MPs in PB increased as well (two-way repeated-measures ANOVA with Bonferroni’s multiple comparison tests, p = 0.0109) ( i ). The absolute count of PMPs on day 2 after CCl 4 injection was higher than that in the control group when platelets started to increase mice) ( j ). Each time point in each animal cohort represents a mean ± S.E.M. of nine mice and two-tailed unpaired t -tests were used unless otherwise specified. Source data are provided as a Source Data file * P < 0.05, ** P < 0.01, *** P < 0.001.
Human Tpo Receptor Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tpo/Human+Thrombopoietin%2FTpo+Antibody/pmc07532443-345-35-39
Average 91 stars, based on 1 article reviews
human tpo receptor antibody - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier

92
InvivoGen recombinant human tpo
a During CCl 4 -induced acute liver injury (ALI), thrombocytosis was detected as an increased peripheral blood (PB) platelet counts in the ALI vs. control (CON) mice ( n = 12 mice, two-way repeated-measures ANOVA with Bonferroni’s multiple comparison tests, p = 0.0045 (Con as control)). Non-treated mice (WT) were set as baseline control. b , c Megakaryocytopoiesis in bone marrow (BM) after CCl 4 injection is shown. On day 8 after injection, representative femur sections stained with CD41 and hematoxylin showed increased levels of CD41-positive cells (Scale bars: 100 μm) ( b ), and a histogram indicated that BM whole megakaryocytic cells (MK, CD41 positive), including mature megakaryocytes (m-MK, CD41, and CD42 double-positive) and megakaryocyte-erythroid progenitors (MEP, CD41, and CD71 double positive), were increased in the ALI mice c . Representative FCM plots are shown in Supplementary Fig. . d The percentage of cells of each ploidy in BM is shown. e , f Liver <t>TPO</t> synthesis was suppressed under ALI, as demonstrated by liver cell qPCR ( e ) and plasma TPO ELISA analyses (two-way repeated measures ANOVA with Bonferroni’s multiple comparison tests, p = 0.0085) ( f ). g PB-PLTs incorporated increased levels of CD62p-positive activated PLT in the ALI mice on day 2 after injection. h – j Platelet-derived <t>microparticles</t> <t>(PMPs)</t> increased in the ALI mice ( n = 12 mice). Compared with those of the control group, the circulating CD41 + microparticles (MPs) increased (two-way repeated-measures ANOVA with Bonferroni’s multiple comparison tests) ( h ), and the proportion of CD41 + /CD62p + PMPs among the CD41 + MPs in PB increased as well (two-way repeated-measures ANOVA with Bonferroni’s multiple comparison tests, p = 0.0109) ( i ). The absolute count of PMPs on day 2 after CCl 4 injection was higher than that in the control group when platelets started to increase mice) ( j ). Each time point in each animal cohort represents a mean ± S.E.M. of nine mice and two-tailed unpaired t -tests were used unless otherwise specified. Source data are provided as a Source Data file * P < 0.05, ** P < 0.01, *** P < 0.001.
Recombinant Human Tpo, supplied by InvivoGen, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tpo/Recombinant+human+TPO/pm38167704-228-24-23
Average 92 stars, based on 1 article reviews
recombinant human tpo - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier

Image Search Results


Journal: Cell Stem Cell

Article Title: Sphingolipid Modulation Activates Proteostasis Programs to Govern Human Hematopoietic Stem Cell Self-Renewal

doi: 10.1016/j.stem.2019.09.008

Figure Lengend Snippet:

Article Snippet: TPO , Milteny Biotec , 130-095-752.

Techniques: Recombinant, SYBR Green Assay, shRNA, Amplification, Sequencing, Control, Plasmid Preparation, Software, Modification

Impairment of hematopoietic function. a) Comparison of changes in CD34 + , b) Comparison of changes in CFU-GM, c) Comparison of changes in BFU-E, d) Comparison of changes in CXCL12, e) Comparison of changes in EPO, f) Comparison of changes in TPO. Note: 'a' indicates P < 0.05 compared with T0, 'b' indicates comparison with T1, and 'c' indicates P < 0.05 compared with the IV group at the same time.

Journal: Journal of Medical Biochemistry

Article Title: Randomized controlled trial of intraosseous access vs. intravenous access in traumatic hemorrhagic shock: Effects on inflammation, hematopoiesis, and coagulation

doi: 10.5937/jomb0-58956

Figure Lengend Snippet: Impairment of hematopoietic function. a) Comparison of changes in CD34 + , b) Comparison of changes in CFU-GM, c) Comparison of changes in BFU-E, d) Comparison of changes in CXCL12, e) Comparison of changes in EPO, f) Comparison of changes in TPO. Note: 'a' indicates P < 0.05 compared with T0, 'b' indicates comparison with T1, and 'c' indicates P < 0.05 compared with the IV group at the same time.

Article Snippet: The following indicators were analyzed: IL-1β (DLB50), IL-6 (D6050B), IL-10 (D1000B), HMGB1 (IC1690G), CXCL12 (MAB310), EPO (DEPRU0), and TPO (BAF288): These markers were quantified using enzyme-linked immunosorbent assay (ELISA) with commercially available kits (R&D Systems).

Techniques: Comparison

a During CCl 4 -induced acute liver injury (ALI), thrombocytosis was detected as an increased peripheral blood (PB) platelet counts in the ALI vs. control (CON) mice ( n = 12 mice, two-way repeated-measures ANOVA with Bonferroni’s multiple comparison tests, p = 0.0045 (Con as control)). Non-treated mice (WT) were set as baseline control. b , c Megakaryocytopoiesis in bone marrow (BM) after CCl 4 injection is shown. On day 8 after injection, representative femur sections stained with CD41 and hematoxylin showed increased levels of CD41-positive cells (Scale bars: 100 μm) ( b ), and a histogram indicated that BM whole megakaryocytic cells (MK, CD41 positive), including mature megakaryocytes (m-MK, CD41, and CD42 double-positive) and megakaryocyte-erythroid progenitors (MEP, CD41, and CD71 double positive), were increased in the ALI mice c . Representative FCM plots are shown in Supplementary Fig. . d The percentage of cells of each ploidy in BM is shown. e , f Liver TPO synthesis was suppressed under ALI, as demonstrated by liver cell qPCR ( e ) and plasma TPO ELISA analyses (two-way repeated measures ANOVA with Bonferroni’s multiple comparison tests, p = 0.0085) ( f ). g PB-PLTs incorporated increased levels of CD62p-positive activated PLT in the ALI mice on day 2 after injection. h – j Platelet-derived microparticles (PMPs) increased in the ALI mice ( n = 12 mice). Compared with those of the control group, the circulating CD41 + microparticles (MPs) increased (two-way repeated-measures ANOVA with Bonferroni’s multiple comparison tests) ( h ), and the proportion of CD41 + /CD62p + PMPs among the CD41 + MPs in PB increased as well (two-way repeated-measures ANOVA with Bonferroni’s multiple comparison tests, p = 0.0109) ( i ). The absolute count of PMPs on day 2 after CCl 4 injection was higher than that in the control group when platelets started to increase mice) ( j ). Each time point in each animal cohort represents a mean ± S.E.M. of nine mice and two-tailed unpaired t -tests were used unless otherwise specified. Source data are provided as a Source Data file * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: Nature Communications

Article Title: Platelet-derived microparticles enhance megakaryocyte differentiation and platelet generation via miR-1915-3p

doi: 10.1038/s41467-020-18802-0

Figure Lengend Snippet: a During CCl 4 -induced acute liver injury (ALI), thrombocytosis was detected as an increased peripheral blood (PB) platelet counts in the ALI vs. control (CON) mice ( n = 12 mice, two-way repeated-measures ANOVA with Bonferroni’s multiple comparison tests, p = 0.0045 (Con as control)). Non-treated mice (WT) were set as baseline control. b , c Megakaryocytopoiesis in bone marrow (BM) after CCl 4 injection is shown. On day 8 after injection, representative femur sections stained with CD41 and hematoxylin showed increased levels of CD41-positive cells (Scale bars: 100 μm) ( b ), and a histogram indicated that BM whole megakaryocytic cells (MK, CD41 positive), including mature megakaryocytes (m-MK, CD41, and CD42 double-positive) and megakaryocyte-erythroid progenitors (MEP, CD41, and CD71 double positive), were increased in the ALI mice c . Representative FCM plots are shown in Supplementary Fig. . d The percentage of cells of each ploidy in BM is shown. e , f Liver TPO synthesis was suppressed under ALI, as demonstrated by liver cell qPCR ( e ) and plasma TPO ELISA analyses (two-way repeated measures ANOVA with Bonferroni’s multiple comparison tests, p = 0.0085) ( f ). g PB-PLTs incorporated increased levels of CD62p-positive activated PLT in the ALI mice on day 2 after injection. h – j Platelet-derived microparticles (PMPs) increased in the ALI mice ( n = 12 mice). Compared with those of the control group, the circulating CD41 + microparticles (MPs) increased (two-way repeated-measures ANOVA with Bonferroni’s multiple comparison tests) ( h ), and the proportion of CD41 + /CD62p + PMPs among the CD41 + MPs in PB increased as well (two-way repeated-measures ANOVA with Bonferroni’s multiple comparison tests, p = 0.0109) ( i ). The absolute count of PMPs on day 2 after CCl 4 injection was higher than that in the control group when platelets started to increase mice) ( j ). Each time point in each animal cohort represents a mean ± S.E.M. of nine mice and two-tailed unpaired t -tests were used unless otherwise specified. Source data are provided as a Source Data file * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: CD63 mouse monoclonal antibody (Santa Cruz Biotechnology), RHOB monoclonal antibody (ABclonal) and GAPDH monoclonal antibody (Cell Signaling Technology) were diluted 1:1000 and used for Western blotting, and 1 μg per mL human TPO antibody or human TPO receptor antibody (R&D Systems) was used to neutralize TPO in PMPs.

Techniques: Control, Comparison, Injection, Staining, Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Derivative Assay, Two Tailed Test

a PMPs from the GFP transgenic mice were isolated and transfused into the same strain of C57BL/6 mice. The percentage of GFP + cells in the Sca-1-positive and Sca-1-negative nucleated cells was analyzed by FCM. b PMP treatment increased the CFU-MK formation of the BM nucleated cells. The mice were irradiated and injected with homologous PMPs or saline (control). Three days later, the BM was harvested for megakaryocytic colony-forming assays. The typical morphology of CFU-MK mouse colonies of different sizes is shown on the left (Scale bars: 100 μm). The statistical analysis is shown on the right. ( n = 4 mice). c PMP enhanced the megakaryocytic lineage proportion of the BM nucleated cells. Representative FCM plots are shown in Supplementary Fig. . d The femur sections stained with hematoxylin and a CD41 antibody indicate more polyploid and CD41 + cells with PMP injection. The tissue samples were harvested 21 days post injection, and the red arrows indicate large, polyploid and CD41-positive megakaryocytes (Scale bars: 100 μm). Representative fields of megakaryocytes in the BM are shown on the left (Scale bars: 10 μm). e PMPs enhanced the megakaryocytic lineage proportion of the PB nucleated cells. Representative FCM plots are shown in Supplementary Fig. . f PMPs improved platelet recovery as indicated by the platelet count (n = 12 mice, two-way repeated-measures ANOVA with Bonferroni’s multiple comparison tests, p = 0.0171). g Plasma TPO was unaffected after PMP treatment. h qPCR indicated that miR-1915-3p was upregulated in the BM nucleated cells 2 days after PMP injection. i Rhob was downregulated in the mouse BM nucleated cells after PMP injection as evaluated by qPCR (left) and Western blotting (right) (normalized to the mouse after saline injection). Transfusion of PMPs overexpressing miR-1915-3p enhanced the megakaryocytic lineage proportion of the BM nucleated cells j and the platelet count in the PB k ( n = 10 mice). Each time point in each animal cohort represents a mean ± SE.M. of 9 mice, P -value. Two-tailed, unpaired Student’s t -tests were used unless otherwise specified. Source data are provided as a Source Data file * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: Nature Communications

Article Title: Platelet-derived microparticles enhance megakaryocyte differentiation and platelet generation via miR-1915-3p

doi: 10.1038/s41467-020-18802-0

Figure Lengend Snippet: a PMPs from the GFP transgenic mice were isolated and transfused into the same strain of C57BL/6 mice. The percentage of GFP + cells in the Sca-1-positive and Sca-1-negative nucleated cells was analyzed by FCM. b PMP treatment increased the CFU-MK formation of the BM nucleated cells. The mice were irradiated and injected with homologous PMPs or saline (control). Three days later, the BM was harvested for megakaryocytic colony-forming assays. The typical morphology of CFU-MK mouse colonies of different sizes is shown on the left (Scale bars: 100 μm). The statistical analysis is shown on the right. ( n = 4 mice). c PMP enhanced the megakaryocytic lineage proportion of the BM nucleated cells. Representative FCM plots are shown in Supplementary Fig. . d The femur sections stained with hematoxylin and a CD41 antibody indicate more polyploid and CD41 + cells with PMP injection. The tissue samples were harvested 21 days post injection, and the red arrows indicate large, polyploid and CD41-positive megakaryocytes (Scale bars: 100 μm). Representative fields of megakaryocytes in the BM are shown on the left (Scale bars: 10 μm). e PMPs enhanced the megakaryocytic lineage proportion of the PB nucleated cells. Representative FCM plots are shown in Supplementary Fig. . f PMPs improved platelet recovery as indicated by the platelet count (n = 12 mice, two-way repeated-measures ANOVA with Bonferroni’s multiple comparison tests, p = 0.0171). g Plasma TPO was unaffected after PMP treatment. h qPCR indicated that miR-1915-3p was upregulated in the BM nucleated cells 2 days after PMP injection. i Rhob was downregulated in the mouse BM nucleated cells after PMP injection as evaluated by qPCR (left) and Western blotting (right) (normalized to the mouse after saline injection). Transfusion of PMPs overexpressing miR-1915-3p enhanced the megakaryocytic lineage proportion of the BM nucleated cells j and the platelet count in the PB k ( n = 10 mice). Each time point in each animal cohort represents a mean ± SE.M. of 9 mice, P -value. Two-tailed, unpaired Student’s t -tests were used unless otherwise specified. Source data are provided as a Source Data file * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: CD63 mouse monoclonal antibody (Santa Cruz Biotechnology), RHOB monoclonal antibody (ABclonal) and GAPDH monoclonal antibody (Cell Signaling Technology) were diluted 1:1000 and used for Western blotting, and 1 μg per mL human TPO antibody or human TPO receptor antibody (R&D Systems) was used to neutralize TPO in PMPs.

Techniques: Transgenic Assay, Isolation, Irradiation, Injection, Saline, Control, Staining, Comparison, Clinical Proteomics, Western Blot, Two Tailed Test